BGI is dedicated to utilizing genomics in order to advance precision medicine for cancer. BGI’s next-generation sequencing assays offer a variety of options, including targeted panels that analyze genes directly linked to specific cancers by well documented scientific research, and also much larger cancer panels designed for cancer analysis and discovery.
BGI’s cancer panels are designed to identify all four classes of actionable genomic alterations, including base substitutions, insertions and deletions, copy number alterations and selected fusions.
Colorectal cancer is the second leading cause of cancer-related mortality in the United States. BGI uses target region capture and NGS to examine 7 genes implicated in CRC targeted therapies, including those recommended in the latest NCCN guidelines.
SUITABLE FOR:
Patients identified with colorectal cancer
TA TIME:
6 working days
SAMPLE:
Fresh/Frozen Tumor tissue, biopsy, FFPE, DNA
TECHNOLOGY:
Target region capture, High-throughput sequencing
Ordering the BGI SENTIS™ Colorectal Cancer (CRC) Panel is easy.
STEP 1
Physician orders test
STEP 2
Blood or saliva sample collected
STEP 3
Sample shipped to BGI and analyzed
STEP 4
Results sent to physician
